Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Venture Life ( (GB:VLG) ) has shared an announcement.
Venture Life Group has disclosed a dealing by a person closely associated with its interim commercial director, in line with market abuse regulations. Lewis Arthur, linked to Sarah Arthur, purchased 2,959 ordinary shares at 67.38p each on 29 January 2026, giving Sarah Arthur a total beneficial holding of 2,959 shares, or 0.002% of the company’s issued share capital.
The transaction, executed on the London Stock Exchange, is relatively small in scale but signals insider alignment with shareholders and maintains transparency around management-related dealings. Such disclosures are important for governance and regulatory compliance, providing investors with visibility into share purchases by individuals connected to senior management.
The most recent analyst rating on (GB:VLG) stock is a Hold with a £67.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.
Spark’s Take on GB:VLG Stock
According to Spark, TipRanks’ AI Analyst, GB:VLG is a Neutral.
Venture Life’s stock score is primarily supported by strong technical indicators and positive corporate events, such as share buybacks and insider buying, which suggest confidence in future prospects. However, the high P/E ratio and profitability challenges weigh down the score, indicating potential overvaluation and financial risks.
To see Spark’s full report on GB:VLG stock, click here.
More about Venture Life
Venture Life Group is an international consumer self-care company operating in the global consumer healthcare sector. Headquartered in the UK, it commercialises products such as Balance Activ for women’s intimate health, Earol for ENT care, Lift and Glucogel for energy and glucose management, and Health & Her for hormonal health, selling through pharmacies, retailers, and e-commerce channels worldwide.
Its products are typically recommended by pharmacists or healthcare practitioners and are distributed directly to retailers in the UK, Ireland, and the U.S., with international markets served via distribution partners. The company focuses on proactive health, product innovation, and commercialisation, positioning itself as a recognised player in the growing global self-care market.
Average Trading Volume: 277,169
Technical Sentiment Signal: Buy
Current Market Cap: £87.37M
For an in-depth examination of VLG stock, go to TipRanks’ Overview page.